|
|
Volumn 302, Issue 4, 2009, Pages 373-374
|
|
New therapies for gi cancers fall short
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CISPLATIN;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
MITOMYCIN C;
OXALIPLATIN;
ANTINEOPLASTIC AGENT;
ADJUVANT THERAPY;
ANUS CANCER;
BREAST CANCER;
CANCER MORTALITY;
CLINICAL FEATURE;
CLINICAL TRIAL;
COLORECTAL CANCER;
DISEASE FREE SURVIVAL;
DRUG WITHDRAWAL;
HIGH RISK PATIENT;
HUMAN;
LUNG CANCER;
MEDICAL RESEARCH;
MORBIDITY;
MULTIMODALITY CANCER THERAPY;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RECTUM CANCER;
SHORT SURVEY;
STANDARDIZATION;
TREATMENT DURATION;
TREATMENT WITHDRAWAL;
CLINICAL PROTOCOL;
COLORECTAL TUMOR;
NOTE;
PRACTICE GUIDELINE;
ANTINEOPLASTIC AGENTS;
CLINICAL PROTOCOLS;
COLORECTAL NEOPLASMS;
HUMANS;
PRACTICE GUIDELINES AS TOPIC;
|
|
EID: 67651238411
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2009.1021 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (0)
|